{"id":"W3040762243","doi":"10.1016/j.cgh.2020.07.012","title":"Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab","year":2020,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Genentech; National Institutes of Health; Bristol-Myers Squibb; Shire; Crohn's and Colitis Foundation; National Institute of Diabetes and Digestive and Kidney Diseases; Boehringer Ingelheim; Tillotts Pharma; Meso Scale Diagnostics; AbbVie; Gilead Sciences; Takeda Pharmaceuticals U.S.A.; Pfizer; Sandoz; Biogen","keywords":"Medicine; Vedolizumab; Ustekinumab; Internal medicine; Gastroenterology; Inflammatory bowel disease; Inflammatory Bowel Diseases; Adalimumab; Tumor necrosis factor alpha; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004754553,0.0003267923,0.002042204,0.0002724407,0.0001943626,0.0003876174,0.0002648957,0.000312123,0.002497892],"category_scores_gemma":[0.001167516,0.0001343872,0.0009434084,0.0003197393,0.0001241457,0.0004060771,0.0002163334,0.0008471733,0.0004157038],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002377441,"about_ca_system_score_gemma":0.0002476099,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002976623,"about_ca_topic_score_gemma":0.000847949,"domain_scores_codex":[0.9995145,0.0001769271,0.00005936718,0.00008717104,0.00009985481,0.00006222897],"domain_scores_gemma":[0.9991025,0.00029253,0.0002596934,0.00007753771,0.00005861473,0.0002092977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1824461,0.003857734,0.1924602,0.001861065,0.008883046,0.001183684,0.0001885362,0.001241031,0.07444286,0.0002544579,0.005619154,0.5275622],"study_design_scores_gemma":[0.01267668,0.06541602,0.8815707,0.0002983976,0.00766544,0.005318572,0.0002644831,0.003428349,0.008099171,0.000386805,0.01480656,0.00006883065],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.971419,0.02225912,0.0004678873,0.0006103297,0.0002245491,0.00004582771,0.0004282593,0.00009652684,0.004448468],"genre_scores_gemma":[0.9968292,0.001762017,0.000296815,0.0001407517,0.0000848238,0.00001977609,0.0003674363,0.000008599945,0.0004904986],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002497892,"threshold_uncertainty_score":0.008356273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01966569239590586,"score_gpt":0.293723077208798,"score_spread":0.2740573848128922,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}